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state (virologically suppressed, treated with ART) was 
0.86. Adding a description of risk resulted in statistically 
significant disutility (i.e., utility decreases): renal risk (dis-
utility = −0.02), bone risk (−0.03), and myocardial infarc-
tion risk (−0.05).
Conclusions Patient concerns and treatment decisions 
were documented via qualitative analysis of Internet forum 
discussions, and the impact of these concerns was quanti-
fied in terms of health state utilities. The resulting disutili-
ties may be useful for differentiating among ARTs in eco-
nomic modeling of treatment for patients with HIV.
Keywords Human immunodeficiency virus · Acquired 
immune deficiency syndrome · Antiretroviral · Treatment 
risk · Utility · Time trade-off
Introduction
Human immunodeficiency virus (HIV), which causes 
acquired immunodeficiency syndrome (AIDS), continues 
to be a major health concern worldwide [1–3]. Treatment 
with antiretroviral therapies (ARTs) has been shown to be 
effective in controlling the virus, preventing symptoms, 
increasing life expectancy, and reducing risk of transmit-
ting the virus to others [4–8]. However, there is grow-
ing awareness of risks associated with commonly used 
ARTs. For example, abacavir, which is a key component 
of several commonly used treatment regimens, has been 
associated with cardiovascular risk, possibly including 
elevated risk of myocardial infarction for some patient 
groups [9–11]. Tenofovir disoproxil fumarate, another 
commonly used ART, has been associated with risk of 
bone mineral density loss [12–14] and renal dysfunction 
[15–17]. Patients’ concerns about these risks could have 
Abstract 
Purpose Despite benefits of antiretroviral therapies 
(ART), people with HIV infection have increased risk of 
cardiovascular disease, kidney disease, and low bone min-
eral density. Some ARTs increase risk of these events. The 
purpose of this study was to examine patients’ perspectives 
of these risks and estimate health state utilities associated 
with these risks for use in cost-utility models.
Methods Qualitative thematic analysis was conducted to 
examine messages posted to the POZ/AIDSmeds Internet 
community forums, focusing on bone, kidney, and cardio-
vascular side effects and risks of HIV/AIDS medications. 
Then, health state vignettes were drafted based on this 
qualitative analysis, literature review, and clinician inter-
views. The health states (representing HIV, plus treatment-
related risks) were valued in time trade-off interviews with 
general population participants in the UK.
Results Qualitative analysis of the Internet forums docu-
mented patient concerns about ART risks, as well as treat-
ment decisions made because of these risks. A total of 208 
participants completed utility interviews (51.4% female; 
mean age 44.6 years). The mean utility of the HIV health 
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an impact on quality of life and treatment preference, 
even among patients who have not experienced the actual 
side effects or medical events.
Cost-utility analyses (CUAs) are frequently con-
ducted to estimate and compare the value of ARTs 
[18–24], and results of these models are used to inform 
decisions regarding allocation of healthcare resources. 
In CUAs, treatments are assessed in terms of cost per 
quality-adjusted life year (QALY) gained [25]. QALYs 
are calculated with health state utilities, which represent 
the strength of preference for a given health state on a 
scale anchored to 0 (dead) and 1 (full health) [26, 27]. 
Although utility values are available for HIV [28–38], no 
previous studies have estimated the disutility (i.e., utility 
decrease) of living with the risks of ARTs, including risk 
of cardiovascular disease, bone mineral density loss, and 
renal dysfunction.
Therefore, the two goals of this study were to (1) explore 
patients’ perspectives of the risks of ART and (2) estimate 
health state utilities associated with these risks so that the 
values may be used in CUAs. This study was conducted 
in two phases, each corresponding to one of the two study 
goals. First, to better understand patients’ experiences of 
living with ART associated risks, a qualitative thematic 
analysis was conducted of public Internet forums in which 
patients with HIV describe their experiences and discuss 
treatment options. Social media data, such as these Internet 
forums, can be a rich source of information from a broad 
range of patients, providing an efficient way to explore the 
patient perspective [39].
Second, the qualitative data gathered in Phase 1 were 
used to support the development of health state vignettes 
that were rated in a time trade-off (TTO) utility valuation. 
This valuation study was designed to identify the disutility 
of living with risks associated with ART. Whereas previ-
ous utility studies have estimated disutility associated with 
experiencing treatment-related adverse events, the current 
study is the first to examine whether there may be a disutil-
ity associated with elevated risk of adverse events, regard-
less of whether the event occurs.
Although some health technology assessment guidelines 
such as those issued by the UK National Institute for Health 
and Care Excellence (2013) have expressed a preference for 
utilities derived from generic preference-based measures, 
these generic instruments are not likely to be sensitive to 
the impact of living with risk [40]. Therefore, the current 
study used a vignette-based approach, which is well-suited 
for isolating the impact of specific treatment-related attrib-
utes on utility. In this case, the disutility of risk was esti-
mated by valuing HIV health states differing only in the 
presence of the risks. The utility difference between two 
otherwise identical health states, one without the risk and 
one with the risk, can be fully attributed to the risk.
Phase 1: methods
Phase 1 overview: thematic analysis of HIV/AIDS 
discussion forum data
Phase 1 involved a qualitative thematic analysis [41–43] of 
messages posted to the POZ/AIDSmeds community forums 
(conducted by co-author TP with input from LM and KC). 
Posts were analyzed for discussion of bone, renal, and car-
diovascular risk associated with ART to support the devel-
opment of health state descriptions valued in Phase 2.
Data source
The asynchronous, text-based public discussion forums 
sponsored by POZ Magazine were selected as the data 
source because of the active community, robust mem-
bership, and high level of interactivity. The forums are 
described by POZ as “a round-the-clock discussion area 
for people with HIV/AIDS, their friends/family/caregiv-
ers, and others concerned about HIV/AIDS,” all of whom 
are considered “members” of the forum for the purposes of 
this study. The forums began in 2006 and had over 23,000 
members by August 2014 when the data were retrieved. All 
messages are publicly visible on the Internet.
There are 18 forums organized by topics including HIV 
transmission, living with HIV, AIDS activism, and treat-
ment and side effects. For the current analysis, all posts 
made to two forums between January 2008 and August 
2014 were retrieved: (1) the English version of “Living 
with HIV” which is the largest forum (191,194 posts in 
12,457 topics) and (2) “Questions about treatment and side 
effects” (32,310 posts in 3710 topics).
Data extraction and analysis
The qualitative data analysis software ATLAS.ti version 
7.0 was used to search the data for terms related to side 
effects and long-term risks of HIV/AIDS medications: car-
dio*, heart*, angina, myocardi*, stroke*, kidney*, renal*, 
bone*, osteo*, fracture*, adverse*, side effect*, and risk*. 
All posts containing these terms were auto-coded, resulting 
in 4122 coded data segments known in ATLAS.ti as “quo-
tations.” These quotations were reviewed for relevance, and 
duplicate and irrelevant quotations were deleted. Quotation 
size was adjusted to capture the relevant section of each 
post, resulting in one quotation per post.
Quotations were analyzed as follows. Initial data search 
terms were consolidated into three major risk codes: bone 
(includes osteo and fracture), kidney (includes renal), and 
heart (includes cardio, stroke, myocardi, and angina). Posts 
were then coded according to four types of risk impact 
in order to document the extent to which patients and 
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clinicians are concerned about these risks (defined in foot-
note of Fig. 1): (1) awareness of risk, (2) patient concerns 
about risk, (3) clinician concerns about risk, and (4) treat-
ment impact resulting from risk. It was possible for a single 




A total of 614 relevant posts were identified across 337 
different discussion topics (threads). The discussion top-
ics that mentioned bone, renal, and cardiovascular risks 
most frequently were titled “Med other than Truvada or 
Epzicom,” “HIV MEDS and Osteoporosis,” “Tenofovir 
associated with significant kidney damage,” “Stopping 
Truvada because of osteoporosis,” “Isentress/Truvada 
side effects,” “Starting Viramune (Nevirapine) + Kivexa 
(Epzicom = 3TC/abacavir),” “Kidneyfailure (GFR39),” 
“Question about switching out Truvada,” “Truvada and 
Borderline osteoporosis…Epzicom substitute?,” and “Atri-
pla and kidney disease.” Some discussion topics lasted only 
a few days, while others lasted for years, such as the “Start-
ing Viramune” topic that lasted for nearly four  years and 
had 156 posts.
As is typical in Internet discussion forums, many more 
people appeared to read posts than contribute posts. For 
example, while only nine posts were made to the “Stopping 
Truvada because of osteoporosis” topic, the posts were 
viewed 1355 times. Similarly, 41 posts were made to the 
thread titled “Tenofovir assoicated [sic] with significant 
kidney damage,” which received 9226 page views. A total 
of 205 members contributed these 614 posts to the forums. 
Thirty-four members made more than three posts related 
to the three risk categories, while 10 members made more 
than 10 posts of interest.
A total of 31 drug names were mentioned in the posts, 
24 of which were mentioned in more than three posts. Tru-
vada was mentioned most frequently (232 posts), followed 
by tenofovir (118), abacavir (63), Atripla (60), Viread (55), 
Epzicom/Kivexa (51), Stribild (45), atazanavir (38), Norvir 
(29), Isentress (26), efavirenz (23), and Kaletra (23). Bone 
and renal risks were discussed most frequently in conjunc-
tion with tenofovir disoproxil fumarate and Truvada, while 
cardiovascular risks were discussed most frequently in con-
junction with Abacavir.
Qualitative coding results
Qualitative coding identified statements mentioning one 
or more of the three risk categories: bone (n = 270), renal 
(n = 336), and/or cardiovascular (n = 142). Of the 614 posts, 
352 conveyed awareness of the risk, 191 indicated patient 
concern, 38 conveyed patients’ reports of clinician concern, 
and 77 reported a change in treatment because of the risk. 
These codes are not mutually exclusive. For example, some 
quotations expressed both clinician concern and treatment 
impact, and these quotations were double-coded.
Within each of the three risk categories, coding revealed 
all four types of risk impact (see Fig.  1 for frequencies 
of codes). Examples of quotations for each type of risk 
are presented in Tables 1 (bone), 2 (renal), and 3 (cardio-
vascular). Members often shared their treatment plans, 
reported their clinical condition (e.g., decreasing bone den-
sity), expressed concern, and requested feedback on pos-
sible treatment changes. Furthermore, patients commonly 
reported a change in pharmaceutical treatment due to either 
actual side effects or risk of side effects.
Overall, the qualitative analysis of social media data 
revealed that ART-related risks are a concern for some 
patients and clinicians, and these risks may influence treat-
ment decisions. Based on a substantial number of quota-







































































Fig. 1  Qualitative analysis of POZ/AIDSmeds community forums: 
frequency of codes indicating impact of risks of antiretroviral treat-
ment. aThere are 18 separate POZ/AIDSmeds forums organized by 
topics. For the current analysis, all posts made to two forums between 
January 2008 and August 2014 were examined: (1) the English ver-
sion of “Living with HIV” and (2) “Questions about treatment and 
side effects.” bFour risk impact codes were used to categorize text of 
posts in online discussion forums using Atlas.ti version 7 qualitative 
data analysis software. Discussion of risk was further categorized 
into three content areas: bone risk, renal risk, and cardiovascular risk. 
Awareness Statements indicating awareness of risks of ART; Patient 
concerns Statements indicating patient concerns or emotions related 
to risks of ART (e.g., worry); Clinician concerns Statements in which 
a patient mentions that his/her healthcare provider was concerned 
about risks of ART; Treatment impact Statements indicating that a 
pharmaceutical treatment was changed due to an actual side effect of 
ART or a known risk of ART; ART antiretroviral treatment
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could have a meaningful impact on patient quality of life 
and treatment preference. Therefore, it was determined that 
it could be useful to quantify this impact in terms of utili-
ties so that these differences among ARTs could be incor-
porated into economic modeling of these treatments.
Phase 2: methods
Phase 2 overview: health state utilities associated 
with risks of antiretroviral treatment
Phase 2 was a vignette-based TTO utility study designed to 
estimate the disutility of living with risks of ART. Health 
state descriptions were drafted based on literature review, 
input from clinicians who treat patients with HIV, and the 
qualitative analysis in Phase 1. Then, the health states were 
refined based on additional clinician interviews and a pilot 
study with general population participants in London, UK. 
Finally, health state utilities were elicited using TTO meth-
ods [25] with general population participants in Edinburgh 
and London, UK. Participants were required to provide 
written informed consent before completing study proce-
dures, and all procedures and materials were approved by 
an independent Institutional Review Board (Ethical and 
Independent Review Services; Study Number 14150-01A).
Health state development
A clinician interview discussion guide was drafted based 
on findings from the qualitative analysis in Phase 1 and 
results of a targeted literature review. This literature review 
was performed to inform the clinician interview questions 
and ensure that the health state descriptions were consist-
ent with published research. Literature searches focused on 
symptoms, impact, and treatment of HIV [7, 8, 44, 45] as 
well as risks associated with ART, including bone [12–14], 
renal [15–17], and cardiovascular risks [9–11].
To further inform health state content, telephone inter-
views were conducted individually with six clinicians (all 
with MD degrees) including specialists in infectious dis-
ease (n = 2), HIV (n = 2), cardiology (n = 1), and nephrol-
ogy (n = 1). First, interviews were conducted with three 
clinicians to gather information for the first draft of the 
Table 1  Qualitative analysis of POZ/AIDSmeds community  forumsa: examples of quotations coded for impact of bone risks associated with 
antiretroviral treatment
a There are 18 separate POZ/AIDSmeds forums organized by topics. For the current analysis, all posts made to two forums between January 2008 
and August 2014 were examined: (1) the English version of “Living with HIV” and (2) “Questions about treatment and side effects”
Codes for impact of bone risks Quotations from POZ/AIDSmeds community forums
Awareness “HIV meds, especially Viread (in Atripla and Truvada) can cause bone loss. I take Vitamin D/calcium also 
about 3 times a week”
“A couple parts of my body are borderline osteoporosis. I am starting to get pain in my right hip and lower back. 
I am understanding Truvada is most likely the cause”
“So I went to the doc today about these bone issues...I’m having...He says the Viread in Atripla can cause bone 
issues, but usually only when someone has been taking it for a long while”
“I looked at some online studies that show that tenofovir is to blame for possible bone issues; even my doctor 
confessed this”
Patient concerns “My concern with Truvada is bone related. I’ve had osteopenia since 2003. No one told me (before or after the 
bone loss) that Tenofovir could cause bone loss…Do you know whether going off Tenofovir would potentially 
improve my osteopenia or at least prevent it from getting worse?”
Clinician concerns “A couple parts of my body are borderline osteoporosis. I am starting to get pain in my right hip and lower back. 
I am understanding Truvada is most likely the cause. My doctor suggested a change to Epzicom”
“I was tested for bone density and the results were I have a certain degree ofosteopenia (loss of bone density). 
My doc said it could be due to the tenofovir contained in Truvada, but said also that many HIV + people 
develop osteopenia even when taking other meds, so she appointed me for a new bone density test by the end 
of this year to see whether it has progressed”
“I started on Atripla…and my bone density test shows some bone thinning…My PCP is thinking it maybe from 
the Atripla or my parathyroid. My ID doctor said, Atripla can in a few cases cause this problem. So, he has 
now started me on Norvir, Epzicon and Reyataz. He doesn’t like one of the ingredients in Truvada long term 
due to bone density stuff, think that was his rationale for not using a once a day pill”
Treatment impact “…diagnosed with osteporosis in feb after 5 years on meds...now I successfully switched to Epzicom instead of 
Truvada. I have dropped tenofovir from my combo because of long-term concerns about bone health”
“I had the same problem 4 years ago. My doc changed my meds from Truvada + Reyataz to Truvada + Intellence 
(Etravirine, an NNRTI). And, a year later, to Kivexa + Intellence. It seemed to partially stop bone density loss. 
But I haven’t recovered the density I lost in those first years on treatment”
“I just switched from Truvada Reyatz + Norvir to Truvada Intellence this week...I have developed osteopenia, 
maybe due to combined effect of Truvada and Reyataz on calcium metabolism”
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health states, with questions focusing on patients’ typical 
experiences with HIV and treatment-related adverse events, 
including symptoms, impact, and treatment. Clinicians’ 
descriptions of living with HIV and associated ART risks 
were generally consistent with each other and consistent 
with findings from the qualitative analysis of social media 
data in Phase 1 of the current study. Interviews were also 
conducted with a nephrologist to inform descriptions of 
chronic kidney disease (CKD) and a cardiologist to gather 
information for the post-myocardial infarction description, 
which was based on a health state used in a previous study 
[46].
Then, draft health states were sent to three of the origi-
nal five clinicians and one new clinician. These follow-
up discussions focused on ensuring that the descriptions 
of ART risks were clear, accurate, and not exaggerated 
beyond what was known based on currently published stud-
ies. This process of refining the health states was iterative, 
and clinicians were interviewed multiple times.
A total of eight health states were drafted. A basic health 
state (i.e., health state 1) designed to provide context for 
the three ART risks described a virologically suppressed 
patient with HIV treated with ART. Three health states 
included health state 1, plus either bone, renal, or cardiac 
treatment-related risks. Four health states included health 
state 1, plus a description of living with actual medical con-
ditions that could arise based on these risks (either CKD or 
post-myocardial infarction). These four health states were 
included to ensure that respondents differentiated between 
living with risk (i.e., health states 2 to 4) and living with 
the actual medical condition (i.e., health states 5 to 8). To 
avoid potential bias associated with the disease labels [47], 
none of the health states explicitly named HIV or AIDS. 
See Appendix A for full health state text.
Pilot study
The health states were tested in a pilot study in November 
and December 2014 with 30 general population partici-
pants in London, UK (16 males; mean age 40.3 years; age 
range 19–67). Each participant valued the health states 
in a TTO task with several time horizons (e.g., 10 years, 
Table 2  Qualitative analysis of POZ/AIDSmeds community  forumsa: examples of quotations coded for impact of renal risks associated with 
antiretroviral treatment
a There are 18 separate POZ/AIDSmeds forums organized by topics. For the current analysis, all posts made to two forums between January 2008 
and August 2014 were examined: (1) the English version of “Living with HIV” and (2) “Questions about treatment and side effects”
Codes for impact of renal risks Quotations from POZ/AIDSmeds community forums
Awareness “Regarding Stribild and the kidney issue. Yes it is an issue. How big of an issue is still a question. Because Stri-
bild is so new there isn’t a lot of data. All we know is that it does affect your kidneys because it causes certain 
kidney tests to be elevated. Combine that with Truvada’s effect on your kidneys and it’s a double whammy. 
Some doctors are hesitant in prescribing it because there are still some unanswered questions (including 
mine)”
“I just started on stribild. I really wanted it because of all the good things I’ve read. I’m getting kidney stuff 
checked frequently and so far haven’t had any reason to believe my kidneys aren’t holding up just fine”
“I hear that Atripla can cause liver and kidney damage long-term and can cause other organ damage. Has any-
one experienced any severity of this?”
Patient concerns “The last week or so I have experienced lower back pain? I know Truvada can be associated with kidney prob-
lems, but I won’t get my first lab test for another 3 weeks so I won’t know if it is my kidneys causing the pain. 
Should I be worried?”
“I’m not thrilled with Truvada since I have concerns about long-term kidney issues that it can possibly cause”
“I take Stribild…The only thing I’m concerned about is the effects it’ll have on my kidneys. I have been doing 
clinical at an HIV clinic for school and I’m astounded at the amount of people that have renal disease requir-
ing dialysis”
Clinician concerns “I wanted to start Stribild and my doc said if I really insisted on it, she would give it to me. However she did 
mention the long-term effects that weren’t known, and I also have a history of kidney stones so she said it’d be 
a possible increased risk for more kidney issues”
“So here’s my question: my nurse, whom I respect and appreciate dearly…She doesn’t like the Truvada very 
much, saying it’s prone to cause renal problems”
“Because of my kidney/kidney stones/always having RBC in my UA, she was leery of Stribild. She said Stribild 
is a good drug but can really be damaging to your kidneys. She said, though my kidney function is fine right 
now, there’s no long-term studies to show how it will effect healthy kidneys over time and also being as how 
I’ve had issues already, she didn’t want to chance it”
Treatment impact “I was taken off Truvada because of low kidney function. The good news is Doc said I might regain function 
after a bit”
“The switch to Epzicom was very uneventful...My kidney numbers are slowly creeping back toward normal—
not sure how long it will take for them to fully recover, but I’m happy that I made the change”
“I was also on Reyataz and had to stop after some kidney dysfunction due to Reyataz”
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20 years) and trading increments (e.g., 5%, 10%). In TTO 
procedures, the duration of time in the health state being 
rated (i.e., the time horizon) varies across studies [48]. 
In the pilot, the time horizon had no apparent impact on 
participants’ responses or comprehension of the task. 
Therefore, it was determined that the subsequent valua-
tion study would use a time horizon of 10 years, which 
maximizes comparability with many previously pub-
lished TTO studies including the influential Measure-
ment and Valuation of Health study [49, 50]. Participants 
generally reported that the health states were clear and 
comprehensible, although minor formatting and text edits 
were made based on specific comments.
Participants
Participants in the pilot and main studies were required 
to be at least 18 years old; able to understand assessment 
procedures; able and willing to provide written informed 
consent; and reside in the UK. Inclusion criteria did not 
specify clinical characteristics because this study aimed 
to estimate utilities for CUAs in submissions to health 
technology assessment agencies, which often prefer that 
utilities represent general population values [40, 51, 52]. 
Participants were recruited via newspapers and online 
advertisements.
Valuation study data collection and statistical analysis 
procedures
Utilities for the final health states were elicited in a valua-
tion study in February 2015 (directed by author LM, with 
interviews conducted by authors LM, KK, ED, and addi-
tional interviewers listed in the acknowledgments sec-
tion). As an introductory task, participants were presented 
with the basic health state (i.e., health state 1) followed by 
the remaining health states in random order and asked to 
rank them in order of preference. Participants then valued 
the health states in a TTO task with a 10-year time hori-
zon and 6-month (i.e., 5%) trading increments. Participants 
were offered a choice between living 10 years in the health 
state being rated or a shorter duration in full health. For 
each health state, choices were presented in an order that 
alternated between longer and shorter amounts of time in 
full health (i.e., 10 years, 0 years, 9.5, 0.5, 9.0, 1.0, 8.5…), 
and utility scores (u) were calculated based on the point of 
indecision as the number of years in full health (x) divided 
by the number of years in the health state being rated 
(u = x/10  years). Each health state considered better than 
dead received a utility score on a scale with the anchors of 
dead (0) and full health (1).
When participants indicated that a health state was 
worse than dead, the task and scoring procedures were 
altered as described in previous literature [53, 54]. Par-
ticipants were offered a choice between immediate death 
Table 3  Qualitative analysis of POZ/AIDSmeds community  forumsa: examples of quotations coded for impact of cardiovascular risks associ-
ated with antiretroviral treatment
a There are 18 separate POZ/AIDSmeds forums organized by topics. For the current analysis, all posts made to two forums between January 2008 
and August 2014 were examined: (1) the English version of “Living with HIV” and (2) “Questions about treatment and side effects”
Codes for impact of 
cardiovascular risks
Quotations from POZ/AIDSmeds community forums
Awareness “I read that Epzicom has moved from ‘preferred’ to ‘alternate status because concerns about possible increased heart 
attack risk”
Patient concerns “…the Abacavir added risk to MI, it is indeed a concern of mine. I am not too happy with this additional risk. Therefore I 
will discuss it with the cardiologist”
“Actually my doc has brought up another boosted PI with Isentress, but I am reluctant, because I think the Norvir booster 
(even at that low dose) is heart toxic…Probably being a little irrational, but still...”
“My concern with Epzicom is that I took it for 5 years. I only switched because of abacavir and the studies that showed 
potential cardio problems”
Clinician concerns “I would like to switch since the doctors are concerned about heart attack risk with ziagen”
Abacavir: “My doctor said he will not prescribe it for me due to the combined facts of my age (48) and I’m a smoker. He 
said the cardiac risk was too high when there were other meds available to me”
Treatment impact “My concern with Epzicom is that I took it for 5 years. I only switched because of abacavir and the studies that showed 
potential cardio problems”
“Ziagen (abacavir) is now said to be linked to heart disease. In my case, with a family history of heart attacks, I am chang-
ing my regime to Truvada plus something else…”
“I switched from Epzicom to Atripla—around 2007—because of general cardiovascular concerns with abacavir—even 
though I don’t have risk factors for heart disease, except I’m a male and 60”
“I switched from Kaletra…I felt Kaletra may have been keeping my HIV under control but it was putting me at risk for 
stroke”
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(choice 1) and a 10-year life span (choice 2) beginning with 
varying amounts of time in the health state being rated, fol-
lowed by full health for the remainder of the 10-year life 
span. The resulting negative utility scores may be calcu-
lated with one of two possible scoring approaches based 
on the TTO choice in which the respondent is indifferent 
between the two alternatives. The first approach yields util-
ities with a possible range of 0 to −∞, using the formula 
−x/(10−x) where x is time in full health, and 10 years is 
the total life span of alternative 2 in the TTO choice (i.e., 
years in the health state being rated plus subsequent years 
in full health). These unbounded negative values can skew 
the distribution of utility estimates for a health state rated 
as worse than dead by even a small number of respondents. 
Therefore, the current study used an alternative bounded 
scoring approach, which is commonly used to avoid highly 
skewed distributions. The formula is −x/10, where x is 
the number of years in full health, and 10 is the number 
of years in the total life span of alternative 2. With this 
approach, the score range of health states worse than death 
are limited or “bounded” between 0 and − 1 [53, 54].
Statistical analyses were completed using SAS ver-
sion 9.2. Continuous variables are summarized in terms of 
means and standard deviations, and categorical variables 
are summarized as frequencies and percentages. Disutilities 
of ART risks and living with related health conditions were 
calculated by subtracting the utility of health state 1 from 
each other health state. Demographic subgroups were com-
pared with Chi-square analyses (for categorical variables) 
and t-tests (for continuous variables). Pairwise t-tests com-
pared health state 1 to every other health state.
Phase 2: results
Sample characteristics
A total of 218 participants attended interviews, ten of 
whom were unable to complete the utility interview pro-
cedures (e.g., insufficient comprehension of the health 
states or TTO procedures). Therefore, the analysis sample 
included 208 participants (105 Edinburgh; 103 London; 
51.4% female; mean age 44.6; age range 18–81). Partici-
pant characteristics are summarized in Table  4. The only 
significant difference between the Edinburgh and London 
subgroups was that a greater percentage of participants in 
Edinburgh reported ethnic/racial background as white (92.4 
vs. 58.3%; p < 0.01). The most commonly reported health 
conditions were anxiety (14%), depression (12%), bone 
Table 4  Demographic 
characteristics
a Other ethnic/racial background includes Arab (n = 2), Kurdish (n = 2), and South American (n = 1)
b Other employment status includes homemaker/housewife (n = 4), student (n = 32), unemployed (n = 10), 
retired (n = 32), and disabled (n = 4)
Demographic characteristics Edinburgh (N = 105) London (N = 103) Total sample (N = 208)
Age (Mean, SD) 45.5 (17.1) 43.7 (16.7) 44.6 (16.9)
Gender (n, %)
 Male 51 (48.6%) 50 (48.5%) 101 (48.6%)
 Female 54 (51.4%) 53 (51.5%) 107 (51.4%)
Ethnic/racial background (n, %)
 White 97 (92.4%) 60 (58.3%) 157 (75.5%)
 Mixed 4 (3.8%) 8 (7.8%) 12 (5.8%)
 Asian 3 (2.9%) 14 (13.6%) 17 (8.2%)
 Black 0 (0.0%) 17 (16.5%) 17 (8.2%)
 Othera 1 (1.0%) 4 (3.9%) 5 (2.4%)
Marital status (n, %)
 Single 51 (48.6%) 55 (53.9%) 106 (51.2%)
 Married/living with partner 42 (40.0%) 33 (32.4%) 75 (36.2%)
 Other 12 (11.4%) 14 (13.7%) 26 (12.6%)
Employment status (n, %)
 Full-time work 38 (36.2%) 33 (32.0%) 71 (34.1%)
 Part-time work 26 (24.8%) 26 (25.2%) 52 (25.0%)
 Otherb 41 (39.0%) 44 (42.7%) 85 (40.9%)
Education level (n, %)
 University degree 43 (41.0%) 42 (40.8%) 85 (40.9%)
 No university degree 62 (59.0%) 61 (59.2%) 123 (59.1%)
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fracture (8%), arthritis (8%), and diabetes (6%). No partici-
pants reported having HIV or AIDS.
TTO utility values
The mean utility for the basic health state (health state 1) 
describing a virologically suppressed HIV patient was 0.86 
(Table  5). Adding the three ART-related risks in health 
states 2, 3, and 4 resulted in disutilities of 0.025 for risk of 
bone problems, 0.018 for risk of renal problems, and 0.049 
for risk of cardiovascular problems. Disutilities associated 
with the medical conditions described in health states 5 to 
8 were larger, ranging from 0.057 for living post-myocar-
dial infarction to 0.596 for stage 5 CKD. T-tests comparing 
the utility of the basic health state to the utility of the other 
health states found that all differences (i.e., disutilities) 
were statistically significant (p < 0.0001).
T-tests were conducted to compare mean utilities and 
disutilities across subgroups. There were no statistically 
significant differences between men and women or between 
the Edinburgh and London subgroups in mean utilities or 
disutilities for any of the health states. A comparison of 
older (>46 years) vs. younger (≤46) respondents, catego-
rized based on a median split, found no differences in util-
ity or disutility for health states 1 to 7. However, younger 
participants had a significantly lower utility for health state 
8 (0.78 vs. 0.83; p = 0.02), as well as a significantly greater 
disutility for this health state (0.07 vs. 0.04; p = 0.01) com-
pared to older participants.
Only two of the health states received any negative valu-
ations. Health state 6 was perceived to be worse than dead 
by four of the 208 respondents, and health state 7 was rated 
worse than dead by 35 respondents. The other six health 
states were perceived to be better than dead by all 208 
respondents.
Discussion
While ARTs have transformed the management and pro-
gression of HIV, the current study suggests that ARTs 
which are not associated with increased bone, renal, or car-
diovascular risks are likely to be preferred over those that 
carry these risks. This investigation was facilitated by two 
methodological innovations. First, this study introduces 
the use of data from patient Internet forums to support 
health state utility research. For previous vignette-based 
utility assessment, health state descriptions have typically 
been drafted based on literature review, clinician inter-
views, and occasionally patient interviews. Current find-
ings suggest that data from online discussion forums can 
add further support for health state vignettes by providing a 
broad picture of patients’ experiences with relevant disease 
and treatment attributes. There is growing awareness that 
social media data can be useful in development of patient-
reported outcomes instruments [39]. The current study sug-
gests that data from Internet discussion forums can also be 
useful for supporting utility research.
The qualitative analysis found that, among patients with 
HIV and their treating clinicians, there is awareness of the 
side effects and long-term risks of ARTs for bone, renal, 
and cardiovascular health. Furthermore, the extracted quo-
tations highlight the potential impact of these risks on emo-
tional well-being, quality of life, and treatment choices. 
Table 5  Time trade-off (TTO) 
utility scores (N = 208)
ART antiretroviral treatment, CKD chronic kidney disease
a Health states 2 to 8 include the basic health state, plus an additional risk (in health states 2–4) or medical 
condition (in health states 5 to 8)
b TTO scores are on a scale anchored with 0 representing dead and 1 representing full health




 1. Basic health state (HIV) 0.862 0.144 0.842–0.881 – –
Basic health state plus ART risks
 2. Risk of renal problems 0.844 0.149 0.824–0.864 0.018 0.043
 3. Risk of bone problems 0.836 0.157 0.815–0.858 0.025 0.078
 4. Risk of cardiovascular problems 0.813 0.158 0.792–0.835 0.049 0.084
Basic health state plus other medical conditions
 5. Stage 3 CKD 0.797 0.175 0.773–0.821 0.065 0.102
 6. Stage 4 CKD 0.672 0.279 0.634–0.710 0.189 0.232
 7. Stage 5 CKD 0.266 0.447 0.205–0.327 0.596 0.440
 8. Post-myocardial infarction 0.805 0.165 0.782–0.827 0.057 0.091
Qual Life Res 
1 3
Overall, this qualitative research suggests there is an impact 
of living with treatment-related risks, even in the absence 
of actual side effects or medical problems.
A second methodological innovation is the focus on dis-
utility of living with risk, regardless of whether the adverse 
event or medical condition actually occurs. Previous stud-
ies have consistently demonstrated that health state utilities 
are significantly reduced as a result of bone problems [55, 
56], renal disease [57–59], and cardiovascular disease [60, 
61]. The current study adds to this research by demonstrat-
ing that awareness of elevated risk of these medical condi-
tions, rather than the conditions themselves, may also have 
a measurable impact on utility. As expected, the disutility 
of risk (health states 2 to 4) was smaller than the disutil-
ity of the medical conditions represented by health states 5 
to 8 and quantified in previous research [55–61]. However, 
the relatively small disutilities associated with ART risks, 
ranging from 0.018 to 0.049 (Table 5), could still have an 
impact on the outcomes of a cost-utility model comparing 
treatments that differ in terms of these risks. In particular, 
cumulative impact of small differences in utility may be 
meaningful when modeling long-term treatment of chronic 
conditions such as HIV.
Although patient Internet discussion forums are a poten-
tially rich source of information, the limitations of online 
data must be acknowledged. Because members of the 
online community participate under pseudonyms, it is not 
possible to know their demographic characteristics or ver-
ify their HIV status and treatment experience. Therefore, 
it is not possible to know the extent to which findings are 
representative of the broader population of patients with 
HIV. Patients who communicate online could be different 
from other patients, and if so, online forum data may repre-
sent a potentially biased sample. For example, patients who 
post in online forums may be more aware of disease and 
treatment characteristics than other patients. Furthermore, 
as in many online communities [62], a small number of 
members of these HIV forums appeared to post frequently, 
while others actively followed the discussions, but posted 
less often. Therefore, quotations do not equally represent 
the entire online community. Future research with a clinic-
based sample could further examine the impact of ART 
risks to replicate findings from the online forums.
Despite limitations, online patient forums are a poten-
tially useful source of information for research in which 
it is important to understand the patient experience. With 
these publicly available discussion texts, it is possible to 
efficiently gain insight into patients’ reactions to disease 
and treatment. Although anonymity of the discussants lim-
its the ability to verify diagnosis and treatment, this ano-
nymity could also be an advantage. In this anonymous set-
ting, patients may be more comfortable raising sensitive 
issues or concerns that they may not discuss with clinicians 
or researchers. Furthermore, because these forums include 
data from many patients, they provide a way to examine 
concerns that affect small numbers of patients, but could 
be important nonetheless. An interview study could fail 
to detect such concerns that may be important to some 
patients. Therefore, it is recommended that online patient 
discussion forums be considered as a potential data source 
for research on the patient perspective.
When interpreting results or using the current utility val-
ues in a CUA, it is also important to consider limitations 
of vignette-based utility assessment. To maximize accurate 
representation of patients’ experiences, the health states 
in this study were carefully drafted based on Internet dis-
cussion forum data, iterative steps of clinician input, and 
detailed literature review. However, health state vignettes 
are inherently limited by the accuracy of information on 
which they are based. These limitations are particularly 
relevant to some of the ART-related risks described in the 
current health states because published research on these 
risks is recent, still developing, and not entirely consistent. 
For example, there is growing consensus that abacavir is 
associated with elevated cardiovascular risk based on sev-
eral large observational studies [63–67], but some analyses 
have not found any statistically significant increase in risk 
[68–70]. Furthermore, while the bone and renal risks asso-
ciated with tenofovir disoproxil fumarate have been demon-
strated across multiple studies, the impact on most patients 
seems to involve changes in surrogate markers such as 
decreased bone mineral density [12–14] and decreased glo-
merular filtration rate [16, 71–73], often with no associated 
symptoms. The clinical significance of these laboratory 
and radiologic changes including the frequency with which 
these initial problems lead to more serious complications, 
such as bone fractures and kidney failure, is not yet known.
Therefore, the health states were drafted to reflect this 
uncertainty of current knowledge so that respondents would 
not overestimate the impact of the risk. For example, rather 
than making a definitive statement, the cardiovascular risk 
health state said “the medication may be associated with a 
small increase in risk of cardiovascular problems.” Future 
research with larger samples and longitudinal designs may 
lead to a better understanding of these risks. If the risks are 
found to be greater or smaller than currently thought, then 
the current results could be underestimating or overestimat-
ing the disutilities of these risks.
One limitation of the current results is that the disu-
tility of each risk is estimated individually, without con-
sidering potential combinations of risks. Some ART 
regimens may be associated with more than one of these 
risks, so modelers must decide how best to combine mul-
tiple disutility values in cost-utility analyses of treat-
ments with multiple risks. Two or three risks could be 
combined additively, but this approach may overestimate 
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the disutility of living with risk, thus failing to provide 
a reasonable estimate of the patient experience. A more 
conservative approach would be to use the disutility of 
greatest magnitude when modeling a treatment regimen 
with multiple risks. For example, to model an ART regi-
men with risk of both renal problems (disutility = 0.018) 
and bone problems (disutility = 0.025), the disutility of 
0.025 may be used.
Despite limitations, qualitative findings highlight the 
impact of living with treatment-related risks. In addition, 
the subsequent TTO valuation study suggests it is feasi-
ble to quantify the impact of living with risk in terms of 
health state utilities. These resulting disutility values for 
bone, renal, and cardiovascular risk may be useful for dif-
ferentiating among ARTs in economic modeling of treat-
ment for patients with HIV.
Acknowledgements This study was funded by Gilead Sciences 
(Foster City, CA). All aspects of the study design, interpretation, and 
decision to submit for publication were determined by the authors. 
The authors would like to thank Gemma Al-Jassar, Zaneta Balantac, 
Katelyn Cutts, Kristen Deger, David Hengerer, Amanda Landrian, 
Hafiz Oko-osi, Alexandrea Russell, Amara Tiebout, and Erica Zaiser 
for assistance with data collection; David Feeny for consulting on the 
study design; Christine Thompson for statistical programming; and 
Amara Tiebout for production assistance.
Funding This study was funded by Gilead Sciences (Foster City, 
CA).
Compliance with ethical standards 
Conflict of interest Two of the authors were employed by Gilead at 
the time this study was conducted (Chung, Fordyce). Four of the au-
thors are or were employed by Evidera, a company that received fund-
ing from Gilead for time spent on this research (Matza, Kim, Davies, 
Stewart). The other authors received funding from Gilead for time 
spent on this research (Paulus, McComsey). All aspects of the study 
design, interpretation, and decision to submit for publication were de-
termined by the authors.
Ethical approval All procedures performed in studies involving 
human participants were in accordance with the ethical standards of 
the institutional and/or national research committee and with the 1964 
Helsinki declaration and its later amendments or comparable ethical 
standards. This article does not contain any studies with animals per-
formed by any of the authors.
Informed consent Written informed consent was obtained from all 
individual participants prior to completing any study measures or pro-
cedures.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
Appendix: complete health state text
1. Basic health state: HIV (this text was also included 
in all other health states)
•	 You have a chronic viral infection. There is currently 
no cure for this infection.
•	 Without treatment, this virus would cause your 
immune system to weaken, which could result in 
life-threatening infections and chronic symptoms (for 
example, pneumonia, fatigue, unhealthy weight loss, 
swollen glands, fevers, chills, night sweats, cough).
•	 You take 1 to 3 tablets every day to keep the infection 
under control.
•	 Because of your treatment, your illness is stable and 
you have no symptoms related to the viral infection. 
The infection does not interfere with your ability to 
work or perform daily activities.
•	 You could spread this virus to other people through 
sexual contact. However, when you are receiving 
treatment, your chance of transmitting the virus is sig-
nificantly reduced.
2. ART associated with risk of renal problems
•	 Your medication is effective for controlling the viral 
infection.
•	 However, the medication is associated with a small 
increase in risk of kidney problems.
•	 A small number of patients who take this medication 
will have a decline in kidney function.
•	 When this happens, there are changes in blood mark-
ers that doctors monitor to see how well the kidneys 
are working.
•	 These changes in blood markers indicate that the kid-
neys are not functioning as well as usual. If this per-
sists or worsens, your doctor might change your medi-
cation to try to avoid serious kidney problems such as 
kidney failure.
•	 Therefore, your kidney function is monitored by your 
doctor every 3–6 months. This is done with blood and 
urine tests.
3. ART with increased risk of bone problems
•	 Your medication is effective for controlling the viral 
infection.
•	 However, the majority of patients treated with your 
medication have a small amount of bone mineral 
density loss. This means that there could be a small 
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decrease in the amount of calcium and other minerals 
in your bones, which could weaken your bones.
•	 The decrease in bone mineral density mostly occurs 
during the first year after starting the medication, but 
appears to stabilize over time.
•	 This decrease in bone mineral density likely does not 
have an impact on most people, but it could lead to a 
greater risk of bone fractures.
•	 This treatment-related risk is greater in people who 
already have other risk factors such as
	– Older age
	– Currently undergoing menopause.
•	 Personal or family history of bone problems.
4. ART associated with risk of cardiovascular events
•	 Your medication is effective for controlling the viral 
infection.
•	 However, the medication may be associated with a 
small increase in risk of cardiovascular problems, such 
as a heart attack, which is a sudden blockage in one of 
the arteries that supplies blood to your heart.
	– A heart attack can cause chest discomfort that feels 
like heaviness, tightness, and a burning feeling, and 
treatment usually involves immediate hospitaliza-
tion.
•	 Some studies suggest that your current risk of heart 
attack may double if you take this medication. Other 
studies have reported a smaller increase in risk.
•	 This treatment-related risk is greater in people who 
already have other risk factors such as
	– Older age
	– Diabetes
	– High blood pressure
	– High cholesterol.
•	 Personal or family history of cardiovascular problems.
5. Chronic kidney disease, stage 3 (renal insufficiency)
•	 Side effect: As a side effect of your medication, you 
have lost 50% of your kidney function. This means that 
your kidneys are not cleaning toxins from your blood as 
well as they used to.
•	 Symptoms: You do not notice any symptoms related to 
your kidney function.
•	 Impact
	– You are able to work and perform your daily routine 
activities.
	– You are able to socialize, and you can participate in 
most of your usual physical activities.
•	 Dietary restrictions
	– To ensure that your condition does not get worse, 
your doctor recommends that you follow dietary 
restrictions.
	– You maintain a diet low in potassium and phos-
phate. Many fruits and vegetables are high in 
potassium, and phosphate is commonly found in 
nuts, cheese, and food with preservatives (or pre-
prepared food). So you eat less of these foods than 
you used to.
•	 Treatment
	– You visit your doctor every 3–4 months. You get a 
blood test at each visit.
	– You take 1 or 2 tablets up to four times per day.
6. Chronic kidney disease, stage 4 (renal insufficiency)
•	 Side effect: As a side effect of your medication, you 
have lost 75% of your kidney function. This means 
that your kidneys are not cleaning toxins from your 
blood as well as they used to.
•	 Symptoms
	– Because of this condition, you sometimes experi-
ence mild to moderate symptoms such as fatigue, 
nausea, and lack of appetite.
	– You sometimes feel generally unwell.
•	 Impact
	– You are usually able to work and perform your 
daily routine activities. However, there are some 
days when you do not feel well enough to work.
	– You are usually able to socialize and participate in 
physical activities, but sometimes you do not feel 
well enough to do so.
•	 Dietary restrictions
	– To ensure that your condition does not get worse, 
your doctor recommends that you follow dietary 
restrictions.
	– You follow a strict diet that limits you from eat-
ing foods high in potassium and phosphate. Many 
fruits and vegetables are high in potassium, and 
phosphate is commonly found in nuts, cheese, and 
food with preservatives (or pre-prepared food). So 
you have to be very careful about the quantity of 
these foods that you eat.
•	 Treatment
	– You visit your doctor every 2–3 months. You get a 
blood test at each visit.
	– You take 1 or 2 tablets with each meal. You also 
take additional tablets at other times each day, 
including the morning and before going to sleep.
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7. Chronic kidney disease, stage 5 (renal failure 
with dialysis)
•	 Side effect: As a side effect of your medication, you 
have lost 90% of your kidney function. This means 
that your kidneys are not cleaning toxins from your 
blood as well as they used to.
•	 Symptoms
	– Because of this condition, you often experience 
significant symptoms such as fatigue, nausea, and 
lack of appetite.
	– You often feel generally unwell.
•	 Impact
	– You are not able to work. However, you can still 
perform your daily routine activities.
	– You are very limited in your ability to socialize or 
participate in physical activities.
•	 Dietary restrictions
	– To ensure that your condition does not get worse, 
your doctor recommends that you follow dietary 
restrictions.
	– You cannot eat foods high in potassium and phos-
phate. Many fruits and vegetables are high in 
potassium, and phosphate is commonly found in 
nuts, cheese, and food with preservatives (or pre-
prepared food). So you eat very little of these 
foods.
•	 Treatment
	– You visit the hospital 3 times each week for dialysis 
treatment.
	– In dialysis, you have a tube inserted into a vein (most 
likely in your neck), which is then attached to a 
machine that cleans your blood.
	– The dialysis process takes about 4 h, and each visit 
takes about half of your day.
	– You take 2 to 5 tablets with each meal. You also take 
additional tablets at other times each day, including 
the morning and before going to sleep.
8. Ongoing effects of prior myocardial infarction
•	 In the past, you had a heart attack, which is a sudden 
blockage in one of the arteries that supplies blood to 
your heart.
•	 You can participate in regular physical activity.
•	 You take several medications each day including aspi-
rin, a cholesterol lowering tablet, and a blood pressure 
lowering tablet.
•	 You see a doctor at least once every year. At these visits, 
you receive a range of tests including a blood test and 
a blood pressure test. At some of these visits, you also 
receive an ECG (heart rhythm test).
•	 You have increased responsibility for managing your 
health. You try to follow your doctor’s recommenda-
tions, including
	– Maintaining a healthy weight
	– Exercising regularly
	– Maintaining a low-fat and low-salt diet
	– Limiting stress (e.g., at work)
	– Avoiding smoking.
•	 Because of your past heart attack, you are at a greater 
risk for experiencing another heart attack or other car-
diovascular problem.
References
 1. De Cock, K. M., Jaffe, H. W., & Curran, J. W. (2012). The evolv-
ing epidemiology of HIV/AIDS. AIDS, 26(10), 1205–1213.
 2. UNAIDS. (2015). How AIDS changed everything—MDG6: 
15  years, 15 lessons of hope from the AIDS response; 380; 
http://www.unaids.org/sites/default/files/media_asset/MDG6Re-
port_en.pdf. Accessed 17 Aug 2015.
 3. World Health Organization (WHO). (Updated July 2015). 
HIV/AIDS Fact Sheet 2015. http://www.who.int/mediacentre/
factsheets/fs360/en/. Accessed 17 Aug 2015.
 4. Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hossein-
ipour, M. C., Kumarasamy, N., et al. (2011). Prevention of HIV-1 
infection with early antiretroviral therapy. The New England 
Journal of Medicine, 365(6), 493–505.
 5. Nakagawa, F., Lodwick, R. K., Smith, C. J., Smith, R., Cambi-
ano, V., Lundgren, J. D., et al. (2012). Projected life expectancy 
of people with HIV according to timing of diagnosis. AIDS, 
26(3), 335–343.
 6. Palella, F. J. Jr., Delaney, K. M., Moorman, A. C., Loveless, M. 
O., Fuhrer, J., Satten, G. A., et  al (1998). Declining morbidity 
and mortality among patients with advanced human immunode-
ficiency virus infection. HIV outpatient study investigators. The 
New England Journal of Medicine, 338(13), 853–860.
 7. Peltzer, K., & Phaswana-Mafuya, N. (2008). The symptom expe-
rience of people living with HIV and AIDS in the Eastern Cape, 
South Africa. BMC Health Services Research, 8, 271.
 8. Rao, D., Nainis, N., Williams, L., Langner, D., Eisin, A., & 
Paice, J. (2009). Art therapy for relief of symptoms associated 
with HIV/AIDS. AIDS Care, 21(1), 64–69.
 9. Durand, M., Sheehy, O., Baril, J. G., Lelorier, J., & Tremblay, 
C. L. (2011). Association between HIV infection, antiretroviral 
therapy, and risk of acute myocardial infarction: a cohort and 
nested case-control study using Quebec’s public health insurance 
database. Journal of Acquired Immune Deficiency Syndromes, 
57(3), 245–253.
 10. Lang, S., Mary-Krause, M., Cotte, L., Gilquin, J., Partisani, M., 
Simon, A., et al. (2010). Impact of individual antiretroviral drugs 
on the risk of myocardial infarction in human immunodeficiency 
virus-infected patients: a case-control study nested within the 
French Hospital Database on HIV ANRS cohort CO4. Archives 
of Internal Medicine, 170(14), 1228–1238.
 11. Worm, S. W., Sabin, C., Weber, R., Reiss, P., El-Sadr, W., Dabis, 
F., et  al. (2010). Risk of myocardial infarction in patients with 
HIV infection exposed to specific individual antiretroviral drugs 
from the 3 major drug classes: the data collection on adverse 
events of anti-HIV drugs (D:A:D) study. The Journal of Infec-
tious Diseases, 201(3), 318–330.
Qual Life Res 
1 3
 12. Bedimo, R., Maalouf, N. M., Zhang, S., Drechsler, H., & Tebas, 
P. (2012). Osteoporotic fracture risk associated with cumula-
tive exposure to tenofovir and other antiretroviral agents. AIDS, 
26(7), 825–831.
 13. Martin, A., Bloch, M., Amin, J., Baker, D., Cooper, D. A., 
Emery, S., et al. (2009). Simplification of antiretroviral therapy 
with tenofovir-emtricitabine or abacavir-Lamivudine: a ran-
domized, 96-week trial. Clinical Infectious Diseases, 49(10), 
1591–1601.
 14. McComsey, G. A., Kitch, D., Daar, E. S., Tierney, C., Jahed, N. 
C., Tebas, P., et  al. (2011). Bone mineral density and fractures 
in antiretroviral-naive persons randomized to receive abacavir-
lamivudine or tenofovir disoproxil fumarate-emtricitabine along 
with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group 
A5224s, a substudy of ACTG A5202. The Journal of Infectious 
Diseases, 203(12), 1791–1801.
 15. Brennan, A., Evans, D., Maskew, M., Naicker, S., Ive, P., Sanne, 
I., et al. (2011). Relationship between renal dysfunction, nephro-
toxicity and death among HIV adults on tenofovir. AIDS, 25(13), 
1603–1609.
 16. Cooper, R. D., Wiebe, N., Smith, N., Keiser, P., Naicker, S., & 
Tonelli, M. (2010). Systematic review and meta-analysis: renal 
safety of tenofovir disoproxil fumarate in HIV-infected patients. 
Clinical Infectious Diseases, 51(5), 496–505.
 17. Sax, P.E., Gallant, J.E., and Klotman, P.E. (2007). Renal safety of 
tenofovir disoproxil fumarate. AIDS Read, 17(2), 90–2, 99–104, 
C3.
 18. Foglia, E., Bonfanti, P., Rizzardini, G., Bonizzoni, E., Restelli, 
U., Ricci, E., et al. (2013). Cost-utility analysis of lopinavir/rito-
navir versus atazanavir + ritonavir administered as first-line ther-
apy for the treatment of HIV infection in Italy: from randomised 
trial to real world. PLoS ONE, 8(2), e57777.
 19. Freedberg, K. A., Losina, E., Weinstein, M. C., Paltiel, A. D., 
Cohen, C. J., Seage, G. R., et al. (2001). The cost effectiveness 
of combination antiretroviral therapy for HIV disease. The New 
England Journal of Medicine, 344(11), 824–831.
 20. Ganguli, A., Wang, J., & Gourley, D. R. (2012). Does combin-
ing antiretroviral agents in a single dosage form enhance quality 
of life of HIV/AIDS patients? A cost-utility study. Research in 
Social and Administrative Pharmacy, 8(2), 157–165.
 21. Maggiolo, F., Colombo, G. L., Di Matteo, S., Bruno, G. M., 
Astuti, N., Di Filippo, E., et al. (2015). Cost-effectiveness analy-
sis of antiretroviral therapy in a cohort of HIV-infected patients 
starting first-line highly active antiretroviral therapy during 6 
years of observation. Patient Related Outcome Measures, 6, 
53–60.
 22. Rosen, S., Long, L., Fox, M., & Sanne, I. (2008). Cost and cost-
effectiveness of switching from stavudine to tenofovir in first-
line antiretroviral regimens in South Africa. Journal of Acquired 
Immune Deficiency Syndromes, 48(3), 334–344.
 23. Sax, P. E., Losina, E., Weinstein, M. C., Paltiel, A. D., Goldie, 
S. J., Muccio, T. M., et  al. (2005). Cost-effectiveness of enfu-
virtide in treatment-experienced patients with advanced HIV dis-
ease. Journal of Acquired Immune Deficiency Syndromes, 39(1), 
69–77.
 24. Simpson, K. N., Luo, M. P., Chumney, E., Sun, E., Brun, S., & 
Ashraf, T. (2004). Cost-effectiveness of lopinavir/ritonavir ver-
sus nelfinavir as the first-line highly active antiretroviral therapy 
regimen for HIV infection. HIV Clinical Trials, 5(5), 294–304.
 25. Brazier, J. R., Ratcliffe, J., Salomon, J. A., & Tsuchiya, A. 
(2007). Measuring and valuing health benefits for economic 
evaluation. New York: Oxford University Press.
 26. Feeny, D. (2005). Preference-based measures: utility and qual-
ity-adjusted life years. In P. Fayers & R. Hays (Eds.), Assessing 
quality of life in clinical trials (pp. 405–431). New York: Oxford 
University Press.
 27. Torrance, G. W. (1986). Measurement of health state utilities for 
economic appraisal. Journal of Health Economics, 5(1), 1–30.
 28. Bayoumi, A. M., & Redelmeier, D. A. (1999). Economic meth-
ods for measuring the quality of life associated with HIV infec-
tion. Quality of Life Research, 8(6), 471–480.
 29. Honiden, S., Sundaram, V., Nease, R. F., Holodniy, M., Lazze-
roni, L. C., Zolopa, A., et al. (2006). The effect of diagnosis with 
HIV infection on health-related quality of Life. Quality of Life 
Research, 15(1), 69–82.
 30. Kauf, T. L., Roskell, N., Shearer, A., Gazzard, B., Mauskopf, 
J., Davis, E. A., et al. (2008). A predictive model of health state 
utilities for HIV patients in the modern era of highly active 
antiretroviral therapy. Value in Health, 11(7), 1144–1153.
 31. Lara, A. M., Wakholi, B. N., Kasirye, A., Munderi, P., Watera, 
C., Lalloo, D. G., et al. (2008). Utility assessment of HIV/AIDS-
related health states in HIV-infected Ugandans. AIDS, 22(Suppl 
1), 123–130.
 32. Mrus, J. M., Yi, M. S., Freedberg, K. A., Wu, A. W., Zackin, 
R., Gorski, H., et al. (2003). Utilities derived from visual analog 
scale scores in patients with HIV/AIDS. Medical Decision Mak-
ing, 23(5), 414–421.
 33. Owens, D. K., Cardinalli, A. B., & Nease, R. F. Jr. (1997). Physi-
cians’ assessments of the utility of health states associated with 
human immunodeficiency virus (HIV) and hepatitis B virus 
(HBV) infection. Quality of Life Research, 6(1), 77–86.
 34. Revicki, D. A., Wu, A. W., & Murray, M. I. (1995). Change in 
clinical status, health status, and health utility outcomes in HIV-
infected patients. Medical Care, 33(4 Suppl), AS173–A82.
 35. Sakthong, P., Schommer, J. C., Gross, C. R., Prasithsirikul, W., 
& Sakulbumrungsil, R. (2009). Health utilities in patients with 
HIV/AIDS in Thailand. Value in Health, 12(2), 377–384.
 36. Schackman, B. R., Goldie, S. J., Freedberg, K. A., Losina, E., 
Brazier, J., & Weinstein, M. C. (2002). Comparison of health 
state utilities using community and patient preference weights 
derived from a survey of patients with HIV/AIDS. Medical 
Decision Making, 22(1), 27–38.
 37. Tengs, T. O., & Lin, T. H. (2002). A meta-analysis of util-
ity estimates for HIV/AIDS. Medical Decision Making, 22(6), 
475–481.
 38. Tran, B. X., Nguyen, L. H., Ohinmaa, A., Maher, R. M., Nong, 
V. M., & Latkin, C. A. (2015). Longitudinal and cross sectional 
assessments of health utility in adults with HIV/AIDS: a system-
atic review and meta-analysis. BMC Health Services Research, 
15, 7.
 39. Humphrey, L., Mahapatra, R., Trundell, D., Kitchen, H. (2015, 
7–11 November 2015). Patient-reported outcomes & patient 
preference research issues: blog it, tweet it, like it, or bin it? 
The Role of Social Media Data in Patient-reported Outcomes 
Research (IP5). Issue Panel: Sesion I at ISPOR 18th Annual 
European Congress. Milan, Italy.
 40. NICE (National Institute for Health and Care Excellence) (2013). 
Process and methods guides: Guide to the methods of technology 
appraisal 2013. London: NICE.
 41. Auerbach, C. F., & Silverstein, L. B. (2003). Qualitative data: an 
introduction to coding and analysis. New York: NYU Press.
 42. Boyatzis, R. E. (1998). Transforming qualitative information: 
thematic analysis and code development. Thousand Oaks, CA: 
Sage Publications.
 43. Gibson, W. J., & Brown, A. (2009). Working with qualitative 
data. London: Sage Publications.
 44. Chiou, P. Y., Kuo, B. I., Lee, M. B., Chen, Y. M., Chuang, P., 
& Lin, L. C. (2006). A programme of symptom management 
for improving quality of life and drug adherence in AIDS/HIV 
patients. Journal of Advanced Nursing, 55(2), 169–179.
 45. Volberding, P. A., & Deeks, S. G. (2010). Antiretroviral therapy 
and management of HIV infection. Lancet, 376(9734), 49–62.
 Qual Life Res
1 3
 46. Matza, L. S., Stewart, K. D., Gandra, S. R., Delio, P. R., Fenster, 
B. E., Davies, E. W., et al. (2015). Acute and chronic impact of 
cardiovascular events on health state utilities. BMC Health Ser-
vices Research, 15, 173.
 47. Rowen, D., Brazier, J., Tsuchiya, A., Young, T., & Ibbotson, R. 
(2012). It’s all in the name, or is it? The impact of labeling on 
health state values. Medical Decision Making, 32(1), 31–40.
 48. Arnesen, T., & Trommald, M. (2005). Are QALYs based on time 
trade-off comparable? A systematic review of TTO methodolo-
gies. Health Economics, 14(1), 39–53.
 49. Dolan, P. (1997). Modeling valuations for EuroQol health states. 
Medical Care, 35(11), 1095–1108.
 50. Dolan, P., Gudex, C., Kind, P., & Williams, A. (1996). The time 
trade-off method: results from a general population study. Health 
Economics, 5(2), 141–154.
 51. CADTH (Canadian Agency for Drugs and Technologies in 
Health). (2006). Guidelines for the economic evaluation of 
health technologies: Canada, Ottawa: CADTH.
 52. PBAC (Pharmaceutical Benefits Advisory Committee). (2013). 
Guidelines for preparing submissions to PBAC, Version 4.4. 
Canberra: Australian Government Department of Health, PBAC.
 53. Matza, L. S., Sapra, S. J., Dillon, J. F., Kalsekar, A., Davies, E. 
W., Devine, M. K., et al. (2015). Health state utilities associated 
with attributes of treatments for hepatitis C. The European Jour-
nal of Health Economics, 16(9), 1005–1018.
 54. Rowen, D., & Brazier, J. (2011). Health Utility Measurement. In 
S. Glied & P. Smith (Eds.), The oxford handbook of health eco-
nomics (pp. 788–813). New York: Oxford University Press.
 55. Matza, L. S., Chung, K., Van Brunt, K., Brazier, J. E., Braun, A., 
Currie, B., et al. (2014). Health state utilities for skeletal-related 
events secondary to bone metastases. The European Journal of 
Health Economics, 15(1), 7–18.
 56. Weinfurt, K. P., Li, Y., Castel, L. D., Saad, F., Timbie, J. W., 
Glendenning, G. A., et  al. (2005). The significance of skeletal-
related events for the health-related quality of life of patients 
with metastatic prostate cancer. Annals of Oncology, 16(4), 
579–584.
 57. Davies, E. W., Matza, L. S., Worth, G., Feeny, D. H., Kostelec, 
J., Soroka, S., et al. (2015). Health state utilities associated with 
major clinical events in the context of secondary hyperparathy-
roidism and chronic kidney disease requiring dialysis. Health 
and Quality of Life Outcomes, 13, 90.
 58. Liem, Y. S., Bosch, J. L., & Hunink, M. G. (2008). Preference-
based quality of life of patients on renal replacement therapy: 
a systematic review and meta-analysis. Value in Health, 11(4), 
733–741.
 59. Wyld, M., Morton, R. L., Hayen, A., Howard, K., & Webster, 
A. C. (2012). A systematic review and meta-analysis of utility-
based quality of life in chronic kidney disease treatments. PLoS 
Medicine, 9(9), e1001307.
 60. Lewis, E. F., Li, Y., Pfeffer, M. A., Solomon, S. D., Weinfurt, K. 
P., Velazquez, E. J., et al. (2014). Impact of cardiovascular events 
on change in quality of life and utilities in patients after myocar-
dial infarction: a VALIANT stud (valsartan in acute myocardial 
infarction). JACC Heart Fail, 2(2), 159–165.
 61. Smith, D. W., Davies, E. W., Wissinger, E., Huelin, R., Matza, 
L. S., & Chung, K. (2013). A systematic literature review of 
cardiovascular event utilities. Expert Review of Pharmacoeco-
nomics and Outcomes Research, 13(6), 767–790.
 62. Preece, J., Nonnecke, B., & Andrews, D. (2004). The top five 
reasons for lurking: improving community experiences for every-
one. Computers in Human Behavior, 20(2), 201–223.
 63. DAD Study Group, et  al. (2007). Class of antiretroviral drugs 
and the risk of myocardial infarction. The New England Journal 
of Medicine, 356(17), 1723–1735.
 64. DAD Study Group, et al. (2008). Use of nucleoside reverse tran-
scriptase inhibitors and risk of myocardial infarction in HIV-
infected patients enrolled in the D:A:D study: a multi-cohort col-
laboration. Lancet, 371(9622), 1417–1426.
 65. Obel, N., Farkas, D. K., Kronborg, G., Larsen, C. S., Pedersen, 
G., Riis, A., et  al. (2010). Abacavir and risk of myocardial 
infarction in HIV-infected patients on highly active antiretroviral 
therapy: a population-based nationwide cohort study. HIV Medi-
cine, 11(2), 130–136.
 66. Palella, F. J. Jr., Althoff, K. N., Moore, R., Zhang, J., Kitahata, 
M., Gange, S. J., et al. (2015, February 23–26). Abacavir use and 
risk for myocardial infarction in the NA-ACCORD. Poster pre-
sented at Conference on Retroviruses and Opportunistic Infec-
tions (CROI). Seattle, WA.
 67. Sabin, C. A., Reiss, P., Ryom, L., De Wit, S., Kirk, O., Weber, 
R., et al. (2014, March 3–6). Is there continued evidence for an 
association between abacavir and myocardial infarction risk? 
Poster presented at 21st Conference on Retroviruses and Oppor-
tunistic Infections (CROI). Boston, MA
 68. Cruciani, M., Zanichelli, V., Serpelloni, G., Bosco, O., Malena, 
M., Mazzi, R., et al. (2011). Abacavir use and cardiovascular dis-
ease events: a meta-analysis of published and unpublished data. 
AIDS, 25(16), 1993–2004.
 69. Ding, X., Andraca-Carrera, E., Cooper, C., Miele, P., Kornegay, 
C., Soukup, M., et al. (2012). No association of abacavir use with 
myocardial infarction: findings of an FDA meta-analysis. Jour-
nal of Acquired Immune Deficiency Syndromes, 61(4), 441–447.
 70. Ribaudo, H. J., Benson, C. A., Zheng, Y., Koletar, S. L., Col-
lier, A. C., Lok, J. J., et al. (2011). No risk of myocardial infarc-
tion associated with initial antiretroviral treatment contain-
ing abacavir: short and long-term results from ACTG A5001/
ALLRT. Clinical Infectious Diseases, 52(7), 929–940.
 71. Fux, C. A., Simcock, M., Wolbers, M., Bucher, H. C., Hirschel, 
B., Opravil, M., et  al. (2007). Tenofovir use is associated with 
a reduction in calculated glomerular filtration rates in the Swiss 
HIV Cohort Study. Antiviral Therapy, 12(8), 1165–1173.
 72. Gallant, J. E., Parish, M. A., Keruly, J. C., & Moore, R. D. 
(2005). Changes in renal function associated with tenofovir diso-
proxil fumarate treatment, compared with nucleoside reverse-
transcriptase inhibitor treatment. Clinical Infectious Diseases, 
40(8), 1194–1198.
 73. Nishijima, T., Kawasaki, Y., Tanaka, N., Mizushima, D., Aoki, 
T., Watanabe, K., et al. (2014). Long-term exposure to tenofovir 
continuously decrease renal function in HIV-1-infected patients 
with low body weight: results from 10 years of follow-up. AIDS, 
28(13).
